Neighbor of punc E11, a novel oncofetal marker for hepatocellular carcinoma

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2353-2363

  Marquardt, Jens Uwe ^a,c   Quasdorff, Maria ^a   Varnholt, Heike ^a,d   Curth, Harald Morten ^a   Mesghenna, Senait ^a   Protzer, Ulrike ^a,b   Goeser, Tobias ^a   Nierhoff, Dirk ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

carcinogenesis; HCC; oncofetal marker; surface marker; tumor development

Indexed keywords

ALPHA FETOPROTEIN; CRE RECOMBINASE; GLYPICAN 3; NEIGHBOR OF PUNC E11 PROTEIN; ONCOFETAL ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CELL LEVEL; CELL SPECIFICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE LEVEL;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; NERVE TISSUE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79953179010     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25567     Document Type: Article

References (39)

1. El-Serag HB Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-34.
2. Fattovich G, Stroffolini T, Zagni I, Donato F, Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50. (Pubitemid 39423368)
3. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
4. Altekruse SF, McGlynn KA, Reichman ME,. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
5. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17. (Pubitemid 37518510)
6. Nakakura EK, Choti MA, Management of hepatocellular carcinoma. Oncology (Williston Park) 2000; 14: 1085-98; discussion 98-102.
7. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS, Suh DJ,. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-80. (Pubitemid 34049056)
8. Zhang BH, Yang BH, Tang ZY,. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
9. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J,. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97. (Pubitemid 36799110)
10. Li D, Mallory T, Satomura S,. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313: 15-19. (Pubitemid 33016686)
11. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM,. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005; 43: 1007-12. (Pubitemid 41627986)
12. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS,. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-21. (Pubitemid 36538688)
13. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB, Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36: S84-92. (Pubitemid 35253467)
14. Gupta S, Bent S, Kohlwes J,. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50. (Pubitemid 38124619)
15. Nierhoff D, Levoci L, Schulte S, Goeser T, Rogler LE, Shafritz DA,. New cell surface markers for murine fetal hepatic stem cells identified through high density complementary DNA microarrays. Hepatology 2007; 46: 535-47. (Pubitemid 47344790)
16. Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V,. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 2005; 41: 1233-40. (Pubitemid 40770275)
17. Si S, Sun Y, Li Z, Ge W, Zhang X, Hu P, Huang Y, Chen G, Song H, Huang Y, Ma B, Li X, et al. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma. Gene Ther 2006; 13: 1603-10. (Pubitemid 44688461)
18. Stahl S, Sacher T, Bechtold A, Protzer U, Ganss R, Hammerling GJ, Arnold B, Garbi N,. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol Lett 2009; 123: 31-7.
19. Schirmacher P, Held WA, Yang D, Biempica L, Rogler CE,. Selective amplification of periportal transitional cells precedes formation of hepatocellular carcinoma in SV40 large tag transgenic mice. Am J Pathol 1991; 139: 231-41.
20. Butel JS, Lednicky JA,. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 1999; 91: 119-34. (Pubitemid 29042689)
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F,. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
22. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS,. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76. (Pubitemid 39265589)
23. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM,. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6. (Pubitemid 38391943)
24. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B,. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-62.
25. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-47. (Pubitemid 46646500)
26. Chen ZM, Crone KG, Watson MA, Pfeifer JD, Wang HL,. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol 2005; 29: 1600-8.
27. Salbaum JM, Kappen C,. Cloning and expression of nope, a new mouse gene of the immunoglobulin superfamily related to guidance receptors. Genomics 2000; 64: 15-23. (Pubitemid 30165070)
28. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS,. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation 1963; 1: 174-80.
29. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-8.
30. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
31. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D,. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-7. (Pubitemid 26080081)
32. Song HH, Shi W, Filmus J,. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997; 272: 7574-7. (Pubitemid 27137302)
33. Lin H, Huber R, Schlessinger D, Morin PJ,. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999; 59: 807-10. (Pubitemid 29086731)
34. Xiang YY, Ladeda V, Filmus J,. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001; 20: 7408-12. (Pubitemid 33078211)
35. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-23. (Pubitemid 38523895)
36. Libbrecht L, Severi T, Cassiman D, Borght SV, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T,. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-11. (Pubitemid 44655475)
37. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16-25. (Pubitemid 36629398)
38. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT,. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-7. (Pubitemid 350155536)
39. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med 2006; 12: 410-6.